Panitumumab (Vectibix)

Pharmacology

  • Monoclonal Ab which acts as an epidermal growth factor receptor (EGFR) inhibitor

Adverse Effects

  • Bronchospasm/Hoarseness (see Obstructive Lung Disease)
    • Epidemiology: may be severe in 1% of cases
    • Clinical: occurs during IV infusion

References

  • xxx